CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
March 15, 2018 16:37 ET
|
BioDelivery Sciences International, Inc.
In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc. (NASDAQ:BDSI), please note that in the second bullet of the Corporate section, the end date of the...
BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
March 15, 2018 16:01 ET
|
BioDelivery Sciences International, Inc.
Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016 BELBUCA® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47% ...
BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
March 14, 2018 07:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15
March 07, 2018 07:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences to Present at the 30th Annual ROTH Conference
March 05, 2018 07:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva
February 06, 2018 07:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA,...
BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada
January 30, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) --
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) and Purdue Pharma (Canada) announced today that BELBUCA® (buprenorphine) buccal...
BioDelivery Sciences Appoints Scott Plesha to President
December 20, 2017 08:45 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Dec. 20, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced the appointment of Scott Plesha, currently Senior Vice President of Sales and...
BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032
December 18, 2017 07:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Dec. 18, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance of BDSI’s...
BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical
December 14, 2017 16:31 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that it has received the required 90-day notice from Collegium Pharmaceutical, Inc....